secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vanda Pharmaceuticals Inc. (VNDA)
CIK:        0001347178
Form:       8-K
Filed at:   2024-10-15T23:59:59+00:00
Accession:  0001193125-24-237220
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vanda rejects Cycle Group's $8.00/share acquisition proposal as undervaluing company
--------------------------------------------------------------------------------

- Board unanimously determined second unsolicited proposal from Cycle Group not in best interests; terms identical to earlier May bid.
- Proposal valued at $8.00/share in cash; Board says it substantially undervalues Vanda.
- Board cited clinical pipeline, commercial presence, and cash balance as sources of greater value.
- Second Cycle Group proposal received Sept 23, 2024; prior proposal May 24, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1347178/000119312524237220/0001193125-24-237220-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1347178/000119312524237220/d840698d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-237220

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer